Diagnosis of primary aldosteronism: Comparison of post-captopril active renin concentration and plasma renin activity

Clinica Chimica Acta

Volumn 411, Issue 9-10, 2010, Pages 657-663

  Wu, Vin Cent ^a   Kuo, Chin Chi ^a   Chang, Hung Wei ^a   Tsai, Chia Ti ^a   Lin, Chien Yu ^b   Lin, Lian Yu ^a   Lin, Yen Hung ^a   Wang, Shuo Meng ^a   Huang, Kuo How ^a   Fang, Cheng Chung ^a   Ho, Yi Luwn ^a   Liu, Kao Lang ^a   Chang, Chin Chen ^a   Chueh, Shih Chieh ^a,c   Lin, Shuei Liong ^a   Yen, Ruoh Fang ^a   Wu, Kwan Dun ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b EN CHU KONG HOSPITAL   (Taiwan)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Aldosterone renin ratio; ARC; Captopril test; PRA; Primary aldosteronism

Indexed keywords

CAPTOPRIL;

ADULT; ALDOSTERONE BLOOD LEVEL; ANIMAL TISSUE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NORMAL VALUE; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ALDOSTERONE; AREA UNDER CURVE; CAPTOPRIL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RENIN; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 77950460566     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.01.027     Document Type: Article

References (43)

1. Young W.F. Minireview: primary aldosteronism-changing concepts in diagnosis and treatment. Endocrinology 2003, 144:2208-2213.
2. Hiramatsu K., Yamada T., Yukimura Y., et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 1981, 141:1589-1593.
3. Plouin P.F., Amar L., Chatellier G. Trends in the prevalence of primary aldosteronism, aldosterone-producing adenomas, and surgically correctable aldosterone-dependent hypertension. Nephrol Dial Transplant 2004, 19:774-777.
4. Stowasser M., Gordon R.D. Primary aldosteronism. Best Pract Res Clin Endocrinol Metab 2003, 17:591-605.
5. Lyons D.F., Kem D.C., Brown R.D., Hanson C.S., Carollo M.L. Single dose captopril as a diagnostic test for primary aldosteronism. J Clin Endocrinol Metab 1983, 57:892-896.
6. Agharazii M., Douville P., Grose J.H., Lebel M. Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension 2001, 37:1440-1443.
7. Mulatero P., Rabbia F., Milan A., et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002, 40:897-902.
8. Rossi G.P., Belfiore A., Bernini G., et al. Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension 2007, 50:424-431.
9. Cartledge S., Lawson N. Aldosterone and renin measurements. Ann Clin Biochem 2000, 37(Pt 3):262-278.
10. McKenna T.J., Sequeira S.J., Heffernan A., Chambers J., Cunningham S. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab 1991, 73:952-957.
11. Danser A.H., Derkx F.H., Admiraal P.J., Deinum J., de Jong P.T., Schalekamp M.A. Angiotensin levels in the eye. Invest Ophthalmol Vis Sci 1994, 35:1008-1018.
12. Gordon D.B., Sachin I.N., Dodd V.N. Heterogeneity of renin substrate in human plasma: effect of pregnancy and oral contraceptives. Proc Soc Exp Biol Med 1976, 153:314-318.
13. Valabhji J., Donovan J., Kyd P.A., Schachter M., Elkeles R.S. The relationship between active renin concentration and plasma renin activity in Type 1 diabetes. Diabet Med 2001, 18:451-458.
14. Unger N., Lopez Schmidt I., Pitt C., et al. Comparison of active renin concentration and plasma renin activity for the diagnosis of primary hyperaldosteronism in patients with an adrenal mass. Eur J Endocrinol 2004, 150:517-523.
15. Derkx F.H., de Bruin R.J., van Gool J.M., et al. Clinical validation of renin monoclonal antibody-based sandwich assays of renin and proren and use of renin inhibitor to enhance prorenin immunoreactivity. Clin Chem 1996, 42:1051-1063.
16. Perschel F.H., Schemer R., Seiler L., et al. Rapid screening test for primary hyperaldosteronism: ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays. Clin Chem 2004, 50:1650-1655.
17. Rayner B.L. Screening and diagnosis of primary aldosteronism. Cardiovasc J S Afr 2002, 13:166-170.
18. Wu VC, Chang HW, Liu KL, Lin YH, Chueh SC, Lin WC, Ho YL, Huang JW, Chiang CK, Yang SY, Chen YM, Wang SM, Huang KH, Hsieh BS, Wu KD; TAIPAI Study Group. Primary aldosteronism: diagnostic accuracy of the losartan and captopril tests. Am J Hypertens 2009;22(8):821-7.
19. TAIPAI Study Group, Wu VC, Chueh SC, Chang HW, Lin LY, Liu KL, Lin YH, Ho YL, Lin WC, Wang SM, Huang KH, Hung KY, Kao TW, Lin SL, Yen RF, Chen YM, Hsieh BS, Wu KD. Association of kidney function with residual hypertension after treatment of aldosterone-producing adenoma. Am J Kidney Dis 2009;54(4):665-73.
20. Wu K.D., Liao T.S., Chen Y.M., et al. Preoperative diagnosis and localization of aldosterone-producing adenoma by adrenal venous sampling after administration of metoclopramide. J Formos Med Assoc 2001, 100:598-603.
21. Hsieh B.S., Chen Y.M., Wu K.D., Chang T.H. Heterogeneous blood pressure response to furosemide and captopril in primary aldosteronism. J Formos Med Assoc 1993, 92:793-796.
22. Funder J.W., Carey R.M., Fardella C., et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008, 93:3266-3281.
23. Chang H.W., Chu T.S., Huang H.Y., et al. Down-regulation of D2 dopamine receptor and increased protein kinase Cmu phosphorylation in aldosterone-producing adenoma play roles in aldosterone overproduction. J Clin Endocrinol Metab 2007, 92:1863-1870.
24. Yen RF, Wu VC, Liu KL, Cheng MF, Wu YW, Chueh SC, Lin WC, Wu KD, Tzen KY, Lu CC; TAIPAI Study Group. The Effectiveness of 131I-6beta-iodomethyl-19-norcholesterol SPECT/CT for primary aldosteronism patients with inconclusive adrenal venous sampling and CT results. J Nucl Med 2009;50(10):1631-7.
25. Doi S.A., Abalkhail S., Al-Qudhaiby M.M., Al-Humood K., Hafez M.F., Al-Shoumer K.A. Optimal use and interpretation of the aldosterone renin ratio to detect aldosterone excess in hypertension. J Hum Hypertens 2006, 20:482-489.
26. Nomura K., Toraya S., Horiba N., Ujihara M., Aiba M., Demura H. Plasma aldosterone response to upright posture and angiotensin II infusion in aldosterone-producing adenoma. J Clin Endocrinol Metab 1992, 75:323-327.
27. Omura M., Sasano H., Fujiwara T., Yamaguchi K., Nishikawa T. Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling. Metabolism 2002, 51:350-355.
28. Novitsky Y.W., Kercher K.W., Rosen M.J., Cobb W.S., Jyothinagaram S., Heniford B.T. Clinical outcomes of laparoscopic adrenalectomy for lateralizing nodular hyperplasia. Surgery 2005, 138:1009-1016. [discussion 1016-1007].
29. Schwartz G.L., Turner S.T. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 2005, 51:386-394.
30. Weinberger M.H., Fineberg N.S. The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med 1993, 153:2125-2129.
31. Landis J.R., Koch G.G. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174.
32. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1:307-310.
33. Passing H. Bablok. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. Eur J Clin Chem Clin Biochem 1983, 21:709-720.
34. Woo M.J., Reiter J.P., Karr A.F. Estimation of propensity scores using generalized additive models. Stat Med 2008, 27:3805-3816.
35. Hanley J.A., McNeil B.J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983, 148:839-843.
36. Tsunoda K., Abe K., Goto T., et al. Effect of age on the renin-angiotensin-aldosterone system in normal subjects: simultaneous measurement of active and inactive renin, renin substrate, and aldosterone in plasma. J Clin Endocrinol Metab 1986, 62:384-389.
37. Ferrari P., Shaw S.G., Nicod J., Saner E., Nussberger J. Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. J Hypertens 2004, 22:377-381.
38. Petersenn S., Unger N., Walz M.K., Mann K. Diagnostic value of biochemical parameters in the differential diagnosis of an adrenal mass. Ann N Y Acad Sci 2006, 1073:348-357.
39. Naomi S., Iwaoka T., Umeda T., et al. Clinical evaluation of the captopril screening test for primary aldosteronism. Jpn Heart J 1985, 26:549-556.
40. Trenkel S., Seifarth C., Schobel H., Hahn E.G., Hensen J. Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism. Exp Clin Endocrinol Diabetes 2002, 110:80-85.
41. Simon D., Hartmann D.J., Badouaille G., et al. Two-site direct immunoassay specific for active renin. Clin Chem 1992, 38:1959-1962.
42. Staessen J.A., Li Y., Richart T. Oral renin inhibitors. Lancet 2006, 368:1449-1456.
43. Tsunoda K., Abe K., Yasujima M., et al. Comparison of immunoreactive renin and plasma renin activity in human plasma. Tohoku J Exp Med 1989, 158:179-186.